| 51 |
26681186 | Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature. | 2016 |
2 |
| 52 |
26763193 | Synthesis of p-O-Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors. | 2016 Feb |
1 |
| 53 |
26829280 | Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. | 2016 Mar 3 |
2 |
| 54 |
26879314 | Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. | 2016 Mar 15 |
2 |
| 55 |
27102572 | EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. | 2016 Jul |
1 |
| 56 |
27118497 | Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors. | 2016 Jun 1 |
1 |
| 57 |
27132165 | Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. | 2016 Aug 8 |
2 |
| 58 |
27135370 | Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. | 2016 Jul 19 |
1 |
| 59 |
27209475 | In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors. | 2016 Aug |
2 |
| 60 |
27387355 | 6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR. | 2016 Aug 15 |
2 |
| 61 |
27491023 | Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. | 2016 Sep 8 |
2 |
| 62 |
25092264 | Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile. | 2015 Feb |
2 |
| 63 |
25462282 | Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. | 2015 Jan 7 |
1 |
| 64 |
25910402 | Quinazoline derivatives as anticancer drugs: a patent review (2011 - present). | 2015 Jul |
2 |
| 65 |
25948633 | EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. | 2015 Sep 1 |
2 |
| 66 |
26238612 | Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3. | 2015 Oct |
2 |
| 67 |
26310890 | Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. | 2015 Sep 18 |
1 |
| 68 |
24269963 | The ErbB/HER family of protein-tyrosine kinases and cancer. | 2014 Jan |
1 |
| 69 |
24387079 | Epidermal growth factor receptor inhibitors: a patent review (2010 - present). | 2014 Mar |
1 |
| 70 |
24928736 | ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. | 2014 Sep |
1 |
| 71 |
24953979 | Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. | 2014 Sep |
1 |
| 72 |
24992720 | QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR. | 2014 |
5 |
| 73 |
25305687 | Optimization of gefitinib analogues with potent anticancer activity. | 2014 Nov 15 |
1 |
| 74 |
25409491 | A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. | 2014 Dec 11 |
1 |
| 75 |
23847159 | 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines. | 2013 Sep |
1 |
| 76 |
23959266 | ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity. | 2013 Dec |
1 |
| 77 |
26417222 | Combined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors. | 2013 |
2 |
| 78 |
21764376 | EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. | 2012 Jan |
2 |
| 79 |
22043991 | Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. | 2012 May |
2 |
| 80 |
22169601 | Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones. | 2012 Jan 1 |
1 |
| 81 |
22309911 | Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. | 2012 Mar |
2 |
| 82 |
22421369 | Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach. | 2012 Jun |
5 |
| 83 |
22818848 | Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases. | 2012 Sep |
1 |
| 84 |
22901387 | Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors. | 2012 Sep 15 |
2 |
| 85 |
22959248 | Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. | 2012 Oct 1 |
1 |
| 86 |
21254978 | Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. | 2011 |
1 |
| 87 |
21294849 | Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK. | 2011 May |
1 |
| 88 |
21677478 | [Erlotinib in non-small cell lung cancer]. | 2011 Jun |
1 |
| 89 |
21789172 | AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. | 2011 |
1 |
| 90 |
21811593 | Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method. | 2011 |
2 |
| 91 |
20222923 | Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib. | 2010 Sep |
1 |
| 92 |
20599299 | Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. | 2010 Sep |
1 |
| 93 |
20627376 | New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: in vitro and docking experiments. | 2010 Sep |
1 |
| 94 |
20657425 | Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database. | 2010 Jun 4 |
1 |
| 95 |
24825983 | 3d QSAR studies on a series of quinazoline derrivatives as tyrosine kinase (egfr) inhibitor: the k-nearest neighbor molecular field analysis approach. | 2010 Jun |
2 |
| 96 |
18771819 | Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives. | 2009 Jul |
1 |
| 97 |
19275520 | Synthesis of quinazolines as tyrosine kinase inhibitors. | 2009 Mar |
1 |
| 98 |
19291100 | Rational design of multitargeted tyrosine kinase inhibitors: a novel approach. | 2009 Apr |
1 |
| 99 |
18465761 | Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase. | 2008 Jul |
2 |
| 100 |
18585943 | Homology models of the mutated EGFR and their response towards quinazoline analogues. | 2008 Oct |
1 |